Triptorelin

Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist, also known as a luteinizing hormone-releasing hormone (LHRH) agonist. It acts on GnRH receptors in the pituitary gland, initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous exposure, these receptors become less responsive, reducing LH and FSH secretion and subsequently lowering sex hormone levels, particularly testosterone in males and oestrogen in females. This hormonal suppression makes triptorelin useful in conditions influenced by sex hormones. It is administered by injection, with the route and schedule depending on the formulation and clinical indication. Long-acting intramuscular formulations are used in conditions such as hormone-dependent prostate cancer and central precocious puberty, while certain short-acting formulations are used in assisted reproductive treatment. Different formulations are not automatically interchangeable because their release characteristics, doses and approved uses vary. Treatment requires medical supervision to assess response and manage possible adverse effects, including an initial temporary increase in sex hormones, changes in mood or sexual function, reduced bone mineral density and metabolic or cardiovascular effects. The choice of regimen depends on the diagnosis, age, treatment objective and locally approved product information.

Triptorelin was developed as a synthetic analogue of naturally occurring GnRH, with sustained stimulation of pituitary receptors leading to suppression of reproductive hormone production during continued treatment. In the United States, the triptorelin pamoate formulation Trelstar received initial FDA approval in 2000 for advanced prostate cancer. Other triptorelin formulations have been authorised in different countries for additional indications, including central precocious puberty and selected assisted reproductive technology protocols. European product information for formulations such as Decapeptyl describes uses in prostate cancer and, depending on the specific product, other hormone-related conditions. In India, regulatory approvals and permitted indications depend on the particular formulation, strength and product authorisation; they should be verified against the current CDSCO-approved prescribing information. Clinical evidence supporting its use includes studies evaluating sustained testosterone suppression in prostate cancer, hormone suppression and growth outcomes in children with central precocious puberty, and prevention of premature LH surges in assisted reproduction. Approval for one formulation or indication should not be assumed to apply to every triptorelin product.

Triptorelin is used primarily for hormone-dependent prostate cancer, where lowering testosterone can slow the growth of cancer cells that depend on this hormone. Certain long-acting formulations are also approved for central precocious puberty, a condition in which puberty begins earlier than expected because of premature activation of the hypothalamic-pituitary-gonadal axis. In assisted reproductive technology, specific short-acting formulations may be used to suppress pituitary activity and help prevent premature LH surges during controlled ovarian stimulation. Depending on the country and product authorisation, triptorelin may also be used in selected treatment protocols for other hormone-sensitive conditions. The approved indication varies by formulation, strength and jurisdiction, so the specific product information should guide prescribing. It may be used alone for hormonal suppression or alongside other treatments, such as radiotherapy for prostate cancer, depending on the treatment plan.

Triptorelin is administered by a healthcare professional, with the route and schedule determined by the formulation and indication. For advanced prostate cancer, long-acting intramuscular formulations may be prescribed as 3.75 mg every four weeks, 11.25 mg every twelve weeks, or 22.5 mg every twenty-four weeks, depending on the approved product. For central precocious puberty, an approved prolonged-release formulation may be given as 22.5 mg intramuscularly every twenty-four weeks. In assisted reproductive treatment, a short-acting formulation may be administered subcutaneously on a daily schedule, according to the fertility specialist’s protocol. These regimens are not interchangeable, and the dose must be selected from the prescribing information for the exact product. Treatment duration depends on the condition, treatment response, tolerability and overall care plan. Clinicians may monitor hormone levels, clinical symptoms, disease status, growth and bone age in children, and relevant metabolic or cardiovascular parameters in adults.

Common side effects depend on the indication and the degree of hormonal suppression. In adults receiving treatment for prostate cancer, these may include hot flushes, sweating, reduced sexual desire, erectile dysfunction, fatigue, headache, mood changes and injection-site discomfort. Hormone suppression may also contribute to weight changes, loss of muscle mass and reduced bone mineral density over time. In children treated for central precocious puberty, injection-site reactions, headache and temporary changes in mood may occur. During fertility treatment, headache, pelvic discomfort or other symptoms related to hormonal changes may be reported. Some patients experience a temporary worsening of symptoms at the beginning of treatment because sex hormone levels may rise initially before falling. The type and severity of adverse effects vary between individuals. Patients should report persistent or troublesome symptoms to their treating clinician rather than changing or stopping treatment themselves.

Triptorelin can cause an initial temporary increase in testosterone or other sex hormones, sometimes worsening symptoms before hormonal suppression develops. In prostate cancer, this initial flare may aggravate bone pain, urinary obstruction or, rarely, complications related to spinal cord compression. Clinicians may consider additional treatment to reduce flare-related risks when appropriate. Longer-term treatment can be associated with loss of bone mineral density, metabolic changes, diabetes, cardiovascular complications and QT-interval prolongation in susceptible patients. Rare but serious concerns include severe allergic reactions, seizures and severe skin reactions. In children treated for central precocious puberty, intracranial hypertension has been reported with GnRH agonists; persistent headache, visual changes or vomiting require prompt assessment. Triptorelin is contraindicated in patients with known serious hypersensitivity to the relevant product and in pregnancy for formulations where this is specified. The medicine should not be used during pregnancy for fertility or other indications unless the applicable product information specifically supports the clinical context. Treatment interruption or discontinuation should be determined by the treating specialist based on the adverse event and indication.

Before starting triptorelin, clinicians should review the diagnosis, relevant medical history, current medicines and the risks associated with hormonal suppression. In adults, particular attention may be needed for cardiovascular disease, diabetes, electrolyte abnormalities, osteoporosis, a history of seizures and medicines that can prolong the QT interval. Patients with urinary obstruction, extensive bone metastases or a risk of spinal cord compression may require close observation when treatment begins. Bone health, blood glucose and other metabolic parameters should be assessed when clinically appropriate, especially during prolonged treatment. For children receiving treatment for central precocious puberty, growth patterns, pubertal signs and skeletal maturation should be monitored. Triptorelin is not appropriate during pregnancy for indications where pregnancy is a contraindication, and pregnancy status should be assessed when relevant. Fertility treatment requires indication-specific protocols and specialist monitoring. Although triptorelin is a peptide analogue and is not typically associated with many classic metabolic drug interactions, medicines that affect cardiac rhythm or hormonal pathways may be clinically important. All prescription medicines, non-prescription products and supplements should be reviewed before treatment.

Confirm the intended indication, formulation, strength and dosing interval before dispensing or administering triptorelin, because immediate-release and prolonged-release products have different schedules and are not automatically interchangeable. Follow the product-specific instructions for reconstitution, injection route, preparation and storage. For prostate cancer, discuss the possibility of an initial symptom flare and establish a plan for monitoring urinary symptoms, bone pain and neurological warning signs. During longer treatment, consider monitoring cardiovascular risk, glucose control and bone health according to the patient’s clinical profile. For central precocious puberty, assess growth velocity, pubertal progression and relevant hormone measurements at the recommended intervals. In assisted reproductive treatment, coordinate administration closely with the fertility specialist’s protocol and the timing of ovarian stimulation. Counsel patients about likely hormonal effects, sexual-function changes, mood symptoms and the importance of attending follow-up appointments. Advise prompt medical review for severe headache with visual symptoms, chest symptoms, new neurological symptoms, severe allergic reactions or rapidly worsening urinary problems. Document treatment response and adverse effects to support decisions about continuing, adjusting or ending therapy.